Selecting targets for cancer prevention: Where do we go from here?

Nature Reviews Cancer

Volumn 6, Issue 11, 2006, Pages 867-874

  Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; SELENIUM; SULINDAC; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; MEDICAL PRACTICE; MOUTH CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER;

BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; HUMANS; NEOPLASMS; RALOXIFENE; TAMOXIFEN;

EID: 33750344255     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc2008     Document Type: Review

References (47)

1. Saccomanno, G. et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 33, 256-270 (1974).
2. Lippman, S. M., Benner, S. E. & Hong, W. K. Cancer chemoprevention. J. Clin. Oncol. 12, 851-873 (1994).
3. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 190, 1371-1388 (1998). This article documents the effectiveness and side-effect profile of tamoxifen in reducing the incidence of breast cancer in high-risk women.
4. Giardiello, F. M. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316 (1993).
5. Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946-1952 (2000). References 4 and 5 show the effectiveness of NSAIDs in regressing colorectal adenomas in the very high-risk familial adenomatous polyposis cohort.
6. The ATBC Study Group. The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. N. Engl. J. Med. 330, 1029-1035 (1994).
7. Omenn, G. S. et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150-1155 (1996). References 6 and 7 show the increased lung cancer incidence in smokers treated with β-carotene in two large randomized placebo-controlled trials.
8. Vogel, V. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295, 2727-2741 (2006).
9. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
10. Greenwald, P. β-Carotene and lung cancer: a lesson for future chemoprevention investigations? J. Natl Cancer Inst. 95, E1-E7 (2003).
11. De Luca, L. M. & Ross, S. A. β-carotene increases lung cancer incidence in cigarette smokers. Nutrition Rev. 54, 178-180 (1996).
12. Meyskens, F. L. & Szabo, E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol. Biomarker Prev. 14, 1366-1369 (2005).
13. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
14. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351-360 (2004).
15. Wattenberg, L. W., Wiedmann, T. S. & Estensen, R. D. Chemoprevention of cancer of the upper respiratory tract of the Syrian Golder hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res. 64, 2347-2349 (2004).
16. Kato, H. et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713-1721 (2004).
17. Langer, C. J. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer 34, 297-303 (2001).
18. Cuzick, J. et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003).
19. Giardiello, F. M. et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346, 1054-1059 (2002).
20. Sandler, R. S. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883-890 (2003).
21. Anderson, W. F., Umar, A. & Hawk, E. T. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin. Pharmacother. 4, 2193-2204 (2003).
22. Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
23. Bach, P. B. et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470-478 (2003).
24. Silverman, S. Jr, Gorsky, M. & Lozada, F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53, 563-568 (1984).
25. Rosin, M. P. et al. Use of allelic loss to predict malignant risk for low grade epithelial dysplasia. Clin. Cancer Res. 6, 357-362 (2000). References 22, 23 and 25 show approaches to identifying individuals at high risk for cancer based primarily on demographic and historical variables (references 22, 23) or molecular abnormalities (reference 25).
26. Lam, S. et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in persons with dysplasia of the bronchial epithelium. Clin. Cancer Res. 10, 6502-6511 (2004).
27. American Cancer Society. Cancer Fact and FIGS 2006. American Cancer Society [online], http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf (2006).
28. Haynes, R. B., Sackett, D. L., Taylor, D. W., Gibson, E. S. & Johnson, A. L. Increased absenteeism from work after detection and labeling of hypertensive patients. N. Engl. J. Med. 299, 741-744 (1978).
29. Cohen, M. H., Johnson, J. R. & Pazdur, R. U. S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) table ts from accelerated approval to full approval. Clin. Cancer Res. 11, 12-19 (2005).
30. Blanke, C. D. & Corless, C. L. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. 23, 274-280 (2005).
31. Dy, G. K. et al. A phase II trial of imatinib (STI571)in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. 16, 1811-1816 (2005).
32. Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60, 5040-5044 (2000).
33. Klein, E. A. et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol. Oncol. 21, 59-65 (2003).
34. Clark, L. C. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276, 1957-1963 (1996).
35. Kelloff, G. J. et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer (AACR Cancer Prevention Task Force). Clin. Cancer Res. 12, 3661-3697 (2006).
36. Dowsett, M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin. Cancer Res. 9, 502S-510S (2003).
37. Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J. Amer. Med. Assoc. 281, 2189-2197 (1999).
38. Hawk, E. T. and Levin, B. Colorectal cancer prevention. J. Clin. Oncol. 23, 378-391 (2005).
39. Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
40. Gann, P. H., Manson, J. E., Glynn, R. J., Buring, J. E. & Hennekens, C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl Cancer Inst. 85, 1220-1224 (1993).
41. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
42. Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873-884 (2006).
43. Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885-895 (2006).
44. Peto, R., Doll, R., Buckley, J. D. & Sporn, M. B. Can Dietary beta-carotene materially reduce human cancer rates? Nature 290, 201-208 (1981).
45. Dorgan, J. F., Schatzkin, A. Antioxidant micronutrients in cancer prevention. Hematol. Oncol. Clin. North. Am. 5, 43-68 (1991).
46. Hennekens, C. et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 145-149 (1996).
47. Baron, J. A. et al. Neoplastic and antineoplastic effects of β-carotene on colorectal adenoma recurrence: results of a randomized trial. J. Natl Cancer Inst. 95, 717-722 (2003).